Neurexis Therapeutics Overview
- Year Founded
-
2020
- Status
-
Private
- Employees
-
4
- Latest Deal Type
-
Grant
- Latest Deal Amount
-
$3M
- Investors
-
4
Neurexis Therapeutics General Information
Description
Developer of therapeutic peptides designed to significantly reduce brain damage from stroke. The company's tool provides an improved peptide with demonstrated efficacy, consisting of two functional domains for the drug to cross the blood-brain barrier, enabling patients to get a neuroprotective option for stroke that would lessen brain damage and long-term health impacts.
Contact Information
Website
www.neurexistherapeutics.comCorporate Office
- Bioscience 1, 12635 East Montview Boulevard
- Suite 100
- Aurora, CO 80045
- United States
Corporate Office
- Bioscience 1, 12635 East Montview Boulevard
- Suite 100
- Aurora, CO 80045
- United States
Neurexis Therapeutics Timeline
Neurexis Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Grant | 18-Sep-2024 | $3M | Completed | Pre-Clinical Trials | ||
| 6. Grant | 19-Apr-2023 | Completed | Pre-Clinical Trials | |||
| 5. Early Stage VC | 23-May-2022 | Completed | Pre-Clinical Trials | |||
| 4. Early Stage VC (Series A) | 07-Mar-2022 | Cancelled | Pre-Clinical Trials | |||
| 3. Grant | 13-Oct-2021 | Completed | Pre-Clinical Trials | |||
| 2. Seed Round | 26-Apr-2021 | $500K | $500K | Completed | Pre-Clinical Trials | |
| 1. Grant | 02-Jun-2020 | $250K | Completed | Startup |
Neurexis Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Seed |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Neurexis Therapeutics Signals
Neurexis Therapeutics Investors (4)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| National Institutes of Health | Government | |||
| National Institutes of Neurological Disorders and Stroke | Government | |||
| VIC Technology Venture Development | Venture Capital | Minority | ||
| Colorado Venture Capital Authority | Government |
Neurexis Therapeutics FAQs
-
When was Neurexis Therapeutics founded?
Neurexis Therapeutics was founded in 2020.
-
Where is Neurexis Therapeutics headquartered?
Neurexis Therapeutics is headquartered in Aurora, CO.
-
What is the size of Neurexis Therapeutics?
Neurexis Therapeutics has 4 total employees.
-
What industry is Neurexis Therapeutics in?
Neurexis Therapeutics’s primary industry is Biotechnology.
-
Is Neurexis Therapeutics a private or public company?
Neurexis Therapeutics is a Private company.
-
What is Neurexis Therapeutics’s current revenue?
The current revenue for Neurexis Therapeutics is .
-
How much funding has Neurexis Therapeutics raised over time?
Neurexis Therapeutics has raised $555K.
-
Who are Neurexis Therapeutics’s investors?
National Institutes of Health, National Institutes of Neurological Disorders and Stroke, VIC Technology Venture Development, and Colorado Venture Capital Authority have invested in Neurexis Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process